The natural history of subclinical hyperthyroidism-a single centre experience

Panagiotis Anagnostis, Zoe A Efstathiadou, Chrisanthi Zouli, Albana Soukia, Athanasios Panagiotou, Eleni Karathanasi, Marina Kita

Department of Endocrinology, Hippokration Hospital of Thessaloniki, Greece

Introduction

The possibility of progression of subclinical hyperthyroidism (SH) to overt hyperthyroidism (OH) is a critical point in deciding whether to treat this situation.

Aims

➤ The aim of this study was to evaluate the rate of progression of SH to OH and the factors influencing this outcome

Patients and methods

- This was a retrospective study at an endocrine referral service in Northern Greece.
- ➤ Data from patients with SH diagnosed between 1996 and 2011 were extracted from the department's electronic database.
- Exclusion criteria:
 - Past history of thyrotoxicosis treated with radioiodine, surgery or antithyroids
 - Thyroiditis
 - Pregnancy/postpartum state
 - Severe illness
 - Pituitary disease

Results

- ➤ 40 patients (37 females/3males) aged 53.9±14.3 years (range 25-76) were included.
- Mean TSH values at baseline were 0.19±0.13 mlU/l.
- ➤ In 18 patients (45%) the **diagnosis** was subclinical Graves' disease (GD), 13 (32.5%) multinodular toxic goitre (MTG) and 9 (22.5%) toxic adenoma (TA).
- ➤ Progression to OH was seen 5 patients, (12.5%), in 2 (11.1%) with GD, 2 (22%) with TA and 1 (7.7%) with MTG, during a mean follow-up time of 34.2±21.3 months.
- ➤OH was observed in 4/36 (11.1%) at 1 year, 1/23 (4.5%) at 2 years, 0/15 (0%) at 3 years and 1/17 (5.9%) at 5 years.
- ➤ Three of 5 patients with SH progressed to OH in 6 months.
- Interestingly, 8 patients at 1 year (22%) normalized thyroid function, 5 (23%) at 2 years, 4 (27%) at 3 years and 6 (35%) at 5 years of follow-up.
- Five of seven (71.4%) with available follow-up data remained euthyroid during follow-up.

Conclusions

- ✓ GD was the most common etiology of SH.
- A very small proportion of patients progressed to OH over 5 years.
- ✓ However, a considerable amount of patients with SH returned to normal thyroid function either for the remainder of follow-up, or only to return to SH state.

References

Schouten B, et al. Clin Endocrinol (Oxf) 2011;74;257-261 Col NF, et al. JAMA 2004;291:239-243 Biondi B, et al. Endocr Rev 2008; 29:76-131